ALPS Advisors’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-36,873
| Closed | -$2.26M | – | 1071 |
|
|
2025
Q3 | $2.26M | Sell |
36,873
-5,836
| -14% | -$304K | 0.01% | 354 |
|
|
2025
Q2 | $2.09M | Sell |
42,709
-14,659
| -26% | -$696K | 0.01% | 365 |
|
|
2025
Q1 | $2.92M | Sell |
57,368
-5,000
| -8% | -$250K | 0.02% | 296 |
|
|
2024
Q4 | $2.82M | Buy |
62,368
+4,199
| +7% | +$180K | 0.02% | 296 |
|
|
2024
Q3 | $2.16M | Sell |
58,169
-1,649
| -3% | -$55.2K | 0.01% | 345 |
|
|
2024
Q2 | $1.83M | Buy |
+59,818
| New | +$1.94M | 0.01% | 352 |
|
|
2022
Q4 | – | Sell |
-39,030
| Closed | -$1.96M | – | 1078 |
|
|
2022
Q3 | $1.96M | Sell |
39,030
-3,294
| -8% | -$161K | 0.02% | 314 |
|
|
2022
Q2 | $1.7M | Sell |
42,324
-31,018
| -42% | -$1.09M | 0.02% | 347 |
|
|
2022
Q1 | $2.74M | Sell |
73,342
-8,474
| -10% | -$326K | 0.03% | 172 |
|
|
2021
Q4 | $3.26M | Sell |
81,816
-4,715
| -5% | -$180K | 0.04% | 187 |
|
|
2021
Q3 | $3.22M | Sell |
86,531
-5,966
| -6% | -$245K | 0.03% | 207 |
|
|
2021
Q2 | $3.91M | Sell |
92,497
-34,731
| -27% | -$1.49M | 0.03% | 191 |
|
|
2021
Q1 | $6.02M | Buy |
127,228
+4,854
| +4% | +$288K | 0.06% | 165 |
|
|
2020
Q4 | $7.47M | Buy |
122,374
+36,031
| +42% | +$2.12M | 0.08% | 154 |
|
|
2020
Q3 | $4.04M | Buy |
86,343
+573
| +0.7% | +$28.2K | 0.06% | 171 |
|
|
2020
Q2 | $4.35M | Sell |
85,770
-25,993
| -23% | -$1.28M | 0.06% | 165 |
|
|
2020
Q1 | $4.99M | Sell |
111,763
-12,350
| -10% | -$622K | 0.08% | 145 |
|
|
2019
Q4 | $5.96M | Buy |
124,113
+6,503
| +6% | +$276K | 0.05% | 148 |
|
|
2019
Q3 | $3.98M | Sell |
117,610
-4,216
| -3% | -$184K | 0.03% | 162 |
|
|
2019
Q2 | $5.48M | Sell |
121,826
-16,638
| -12% | -$657K | 0.04% | 150 |
|
|
2019
Q1 | $5.21M | Buy |
138,464
+21,862
| +19% | +$734K | 0.04% | 164 |
|
|
2018
Q4 | $4M | Buy |
116,602
+33,936
| +41% | +$1.22M | 0.03% | 173 |
|
|
2018
Q3 | $3.88M | Buy |
82,666
+15,261
| +23% | +$631K | 0.03% | 185 |
|
|
2018
Q2 | $2.27M | Buy |
67,405
+11,757
| +21% | +$367K | 0.01% | 218 |
|
|
2018
Q1 | $1.51M | Buy |
55,648
+9,673
| +21% | +$245K | 0.01% | 242 |
|
|
2017
Q4 | $767K | Buy |
45,975
+5,213
| +13% | +$88.2K | 0.01% | 314 |
|
|
2017
Q3 | $816K | Buy |
40,762
+9,571
| +31% | +$187K | 0.01% | 276 |
|
|
2017
Q2 | $572K | Buy |
31,191
+1,667
| +6% | +$22.5K | ﹤0.01% | 386 |
|
|
2017
Q1 | $291K | Sell |
29,524
-3,455
| -10% | -$41.8K | ﹤0.01% | 696 |
|
|
2016
Q4 | $360K | Sell |
32,979
-10,681
| -24% | -$112K | ﹤0.01% | 644 |
|
|
2016
Q3 | $612K | Sell |
43,660
-4,475
| -9% | -$36.4K | 0.01% | 248 |
|
|
2016
Q2 | $338K | Buy |
48,135
+9,594
| +25% | +$70.4K | ﹤0.01% | 556 |
|
|
2016
Q1 | $248K | Sell |
38,541
-6,606
| -15% | -$115K | ﹤0.01% | 588 |
|
|
2015
Q4 | $1.46M | Sell |
45,147
-8,496
| -16% | -$250K | 0.01% | 192 |
|
|
2015
Q3 | $1.43M | Buy |
53,643
+20,052
| +60% | +$858K | 0.02% | 189 |
|
|
2015
Q2 | $1.62M | Buy |
33,591
+16,823
| +100% | +$982K | 0.01% | 180 |
|
|
2015
Q1 | $1.02M | Buy |
+16,768
| New | +$1.02M | 0.01% | 186 |
|
Other funds holding PTCT
RI
AC
ALPS Advisors's PTCT Position: Q4 2025 in Review
ALPS Advisors sold out of PTC Therapeutics (PTCT) in Q4 2025, closing a stake of 36,873 shares — an estimated $2.26M sold.
ALPS Advisors first reported a position in PTCT in Q1 2015 and held it in 37 quarters. The position peaked at $7.47M in Q4 2020. 353 funds tracked by Wall St. Rank hold PTCT as of Q4 2025.
- ALPS Advisors reported no remaining PTC Therapeutics position as of Q4 2025 after selling out during the quarter.
- ALPS Advisors sold 36,873 PTC Therapeutics shares in Q4 2025, an estimated $2.26M.
- ALPS Advisors first reported a position in PTC Therapeutics in Q1 2015 and held it in 37 quarters.
- ALPS Advisors's PTC Therapeutics position peaked at $7.47M in Q4 2020.
- 353 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2025.
Based on ALPS Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.